L'intérêt à découvert pour Humacyte donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Humacyte. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Humacyte (NASDAQ:HUMA) Stock, Rapport sur les intérêts à découvert

Humacyte

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Humacyte Inc

HUMAN PHEROMONE SCIENCE by Human Pheromone Sciences, Inc.

Human - United States Dollar

HUMAN HOLDINGS CO LTD by Human Holdings Co., Ltd.

Human Holdings Co Ltd

HUMAN UNITEC INTL INC by Human Unitec International, Inc.

Human Unitec International Inc

Humana Inc

Humanigen Inc

Humankind US Stock ETF

Humanscape

Humatech Inc

Whales with a lot of money to spend have taken a noticeably bullish stance on Airbnb.
Looking at options history for Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) we detected 39 trades.
If we consider the specifics of each trade, it is accurate to state that 43% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 14 are puts, for a total amount of $1,316,369 and 25, calls, for a total amount of $11,528,486.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $115.0 to $210.0 for Airbnb during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Airbnb's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Airbnb's whale activity within a strike price range from $115.0 to $210.0 in the last 30 days. 
<h3>Airbnb Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739466042_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$35.2</td>
<td>$32.45</td>
<td>$34.0</td>
<td>$140.00</td>
<td>$9.8M</td>
<td>392</td>
<td>2.9K</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.3</td>
<td>$4.9</td>
<td>$5.15</td>
<td>$137.00</td>
<td>$673.5K</td>
<td>550</td>
<td>1.5K</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.55</td>
<td>$5.5</td>
<td>$5.55</td>
<td>$138.00</td>
<td>$179.2K</td>
<td>82</td>
<td>46</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.9</td>
<td>$4.75</td>
<td>$4.9</td>
<td>$143.00</td>
<td>$175.2K</td>
<td>750</td>
<td>363</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.5</td>
<td>$6.35</td>
<td>$6.5</td>
<td>$140.00</td>
<td>$130.0K</td>
<td>4.9K</td>
<td>417</td>
</tr>
</tbody>
</table>

<h3>About Airbnb</h3>
Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of Sept. 30, 2024. Listings from the company's over 5 million hosts are spread over almost every country in the world. In 2023, 50% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.
In light of the recent options history for Airbnb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Airbnb</h3>
<ul>
<li>With a trading volume of 2,682,455, the price of ABNB is down by -0.89%, reaching $139.28.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>Expert Opinions on Airbnb</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $96.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Underweight rating on Airbnb, maintaining a target price of $96. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Airbnb with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

ABNB

Unpacking the Latest Options Trading Trends in Airbnb

Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 75% leaning bullish and 18% bearish. Among these notable options, 14 are puts, totaling $579,028, and 2 are calls, amounting to $283,180.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $320.0 for Humana over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $230.0 to $320.0 over the preceding 30 days.
<h3>Humana Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739466037_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$7.9</td>
<td>$6.6</td>
<td>$7.9</td>
<td>$260.00</td>
<td>$197.5K</td>
<td align="right">69</td>
<td align="right">250</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$48.9</td>
<td>$47.6</td>
<td>$47.6</td>
<td>$250.00</td>
<td>$85.6K</td>
<td align="right">448</td>
<td align="right">18</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.9</td>
<td>$6.4</td>
<td>$6.8</td>
<td>$257.50</td>
<td>$83.6K</td>
<td align="right">86</td>
<td align="right">125</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.8</td>
<td>$22.5</td>
<td>$22.5</td>
<td>$250.00</td>
<td>$49.5K</td>
<td align="right">131</td>
<td align="right">22</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$26.0</td>
<td>$22.5</td>
<td>$22.7</td>
<td>$250.00</td>
<td>$45.4K</td>
<td align="right">131</td>
<td align="right">179</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>Trading volume stands at 334,823, with HUM's price down by -1.33%, positioned at $256.57.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $277.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Humana with a target price of $288. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $283. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Humana with a target price of $270. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $290. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Humana, maintaining a target price of $255. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Check Out What Whales Are Doing With HUM

When <a href="https://www.benzinga.com/news/25/02/43581353/mrbeast-plans-to-buy-out-a-whole-walmart-store-to-break-shaqs-70k-record-but-shaq-tells-him-he-tried-during-katrina-they-wont-let-you">Shaquille O'Neal and MrBeast</a> sat down for <a href="https://youtu.be/uLJ9oXEV3RY?si=LSBCB4_sWu4QHu2n">The Big Podcast</a> in January 2025, things quickly escalated – as they often do when two larger-than-life personalities collide. What started as a casual chat about Beast Games, Kobe Bryant and even the idea of buying TikTok turned into Shaq challenging MrBeast to test their endurance in one of the most mentally grueling environments: an anechoic chamber, the world's quietest room.
"I keep seeing this soundproof room – something they say if you stay in there for an hour, you get $500,000 or $5 million," Shaq said. "Me or you can do that. I'm confident enough to say I can do it, but I know you can do it."
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
</ul>
At first glance, sitting in silence for an hour might seem like an easy task. However, anechoic chambers are designed to eliminate all external noise, making the human body its own soundscape. Within minutes, people begin hearing their own heartbeat, blood flow, and even bones shifting. The experience is so unnerving that most can't handle it for long. While Shaq claimed the record was 58 minutes, reports suggest the longest confirmed endurance time is around 45 minutes.&nbsp;
According to CNN, despite widespread rumors, there is no official world record for the longest time spent in an anechoic chamber, and such endurance challenges are not formally recognized or encouraged.&nbsp;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
MrBeast, who has buried himself alive, spent days in solitary confinement, and tackled extreme endurance challenges, was instantly intrigued. "I know what you're talking about. Every time I see someone tap out, I'm like … what? Like, because it's quiet?"
On the other hand, Shaq had no doubts about his ability to power through. "Bro, my father was a drill sergeant," he said with total confidence. "I'll just go to sleep."
The idea of Shaq and MrBeast facing off in a test of mental resilience is the kind of spectacle fans would love to see. While one became a dominant force in basketball and the other redefined digital entertainment, both share a key trait: they do everything on a <a href="https://www.benzinga.com/personal-finance/25/01/42788843/nba-legend-shaq-says-he-didnt-even-start-spending-his-nba-checks-until-he-had-kids-i-had-so-much-coming-in">massive scale</a>.
See Also: According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions">Join the first company to bring blockchain payments to Salesforce early with just $100.</a>
Beyond their competitive spirits, Shaquille O'Neal and MrBeast have used their <a href="https://www.benzinga.com/personal-finance/25/01/43077262/nba-legend-shaq-spotted-a-young-man-buying-an-engagement-ring-in-zales-when-he-swooped-in-and-paid-for-it-tell-your-girlfriend-i-got-it">success to make a real difference</a>. Shaq's Shaquille O'Neal Foundation provides scholarships, supports children's health initiatives and funds life-changing opportunities for underserved youth. He's also known for spontaneous generosity, from covering medical bills to buying families new homes. MrBeast, through Beast Philanthropy, has raised millions for environmental causes like TeamTrees and TeamSeas, rebuilt homes for disaster victims and provided clean drinking water to communities in need.
Now, the only question is – will this challenge happen? And if it does, who cracks first? Either way, it's bound to be legendary.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>

Personal Finance

'Bro, My Father Was A Drill Sergeant'– Shaq Dares MrBeast To See Who Can Last Longer In A Soundproof Room For $500,000

RBC Capital analyst Mike Dahl maintains SiteOne Landscape Supply (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITE#NYSE">SITE</a>) with a Sector Perform and raises the price target from $129 to $136.

News

Price Target

Analyst Ratings

SITE

RBC Capital Maintains Sector Perform on SiteOne Landscape Supply, Raises Price Target to $136

RBC Capital analyst Marina Calero maintains Sibanye Stillwater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) with a Sector Perform and lowers the price target from $6 to $4.25.

SBSW

RBC Capital Maintains Sector Perform on Sibanye Stillwater, Lowers Price Target to $4.25

Oppenheimer analyst Christopher Glynn maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Outperform and lowers the price target from $44 to $40.

Oppenheimer Maintains Outperform on Sensata Technologies, Lowers Price Target to $40

Trading Ideas

MBRX

Moleculin Biotech Shares Halted On Circuit Breaker To The Upside, Stock Now Up 714.3%

RBC Capital analyst Conor McNamara maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Outperform and lowers the price target from $64 to $61.

QDEL

RBC Capital Maintains Outperform on QuidelOrtho, Lowers Price Target to $61

Moleculin Biotech Shares Resume Trading

RBC Capital analyst Daniel Perlin maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Sector Perform and raises the price target from $105 to $108.

QTWO

RBC Capital Maintains Sector Perform on Q2 Holdings, Raises Price Target to $108

Oppenheimer analyst Jason Helfstein maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Outperform and lowers the price target from $135 to $115.

Oppenheimer Maintains Outperform on Trade Desk, Lowers Price Target to $115

IPOs

AARD

Aardvark Therapeutics Shares Open For Trade At 15.18/Share; IPO Priced At $16/Share On 5.89M Shares

KRMN

Karman IPO Price Opens At $30.225/Share; IPO Priced At $22/Share On 23M Shares

Oppenheimer analyst Rupesh Parikh maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Outperform and raises the price target from $87 to $93.

Oppenheimer Maintains Outperform on Prestige Consumer, Raises Price Target to $93

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/02/2025-02-13_08h40_07.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Hotter PPI</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-hotter-inflation-ppi-inflation-spy-mc-02132025">click here</a> for a chart of SPDR S&amp;P 500 ETF Trust (SPY) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>The chart shows the Consumer Price Index (CPI) dip was aggressively bought yesterday.</li>
<li>The chart shows that the stock market is now back at the low band of the micro resistance zone.</li>
<li>Based on historical precedence, the stock market should have fallen over 1000 DJIA points yesterday on hotter CPI data. The momo crowd extremely aggressively bought the dip, resulting in the stock market closing down only 225 DJIA points.</li>
<li>A new narrative from momo gurus has taken hold that inflation no longer matters because of their complete faith in President Trump's leadership.</li>
<li>The stock market also completely ignored Powell's response to higher CPI data.&nbsp; Powell said:
<ul>
<li>Policy will remain restrictive.</li>
<li>Progress is being made on inflation, but it is not yet at the goal.</li>
</ul>
</li>
<li>Last night, stock market futures ran even higher on aggressive momo buying.&nbsp; In the early trade, the stock market gave up gains in stock futures prior to the release of the Producer Price Index (PPI), as many investors took advantage of the strength to sell on concerns that Trump will announce reciprocal tariffs today.</li>
<li>Inflation at the producer level came hotter than expected.&nbsp; Here are the details:
<ul>
<li>Headline PPI came at 0.4% vs. 0.2% consensus.</li>
<li>Core PPI came at 0.3% vs. 0.3% consensus.</li>
<li>Of utmost importance to prudent investors is that the PPI data for prior months has been significantly revised upwards.&nbsp;</li>
</ul>
</li>
<li>The momo crowd initially extremely aggressively bought stocks on hotter PPI.&nbsp; The buying was met by selling from investors who took notice of the prior revisions to the upside.&nbsp; The momo crowd bought the dip as other investors sold.</li>
<li>A battle royale is shaping up between investors who are concerned about inflation and investors who believe inflation is not of consequence anymore because of President Trump's leadership.</li>
<li>In The Arora Report analysis, there is merit to President Trump&#8217;s leadership in pro-growth policies, reducing waste and fraud in the government, deregulation, tax cuts and tariffs.&nbsp; Having said that, it is a grave mistake to ignore inflation.&nbsp;&nbsp;</li>
<li>Back in September 2024, when the Fed cut interest rates by 50 bps, we shared with you the contrary Arora call that the Fed was making a policy mistake.&nbsp; The CPI and PPI data, especially the prior month revisions, now confirm that the Fed made a mistake in September.</li>
<li>The Arora Report has made dozens of contrary calls over decades regarding the Fed.&nbsp; One hundred percent of the prior calls have proven correct.&nbsp; So far, the call about the September 2024 rate cuts has proven spot on.&nbsp; Not only has the subsequent inflation data shown that the Fed made a mistake, but the yield on the 10-year bond has risen about 100 bps since the Fed's 50 bps rate cut.</li>
<li>Initial jobless claims came at 213K vs. 217K consensus.</li>
<li>Retail sales will be released tomorrow at 8:30am ET.</li>
<li>Prudent investors need to be aware that President Trump is threatening to impose reciprocal tariffs later today.&nbsp; There is a press conference scheduled for 1pm ET.&nbsp; Consider staying alert.</li>
</ul>
<h4 class="wp-block-heading">Layoffs</h4>
More layoffs are coming in tech.
In important news, oil giant Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) will cut 20% of its workforce.
Seventy-five thousand federal workers have opted into Trump's deferred resignation program.
Ultimately, these layoffs will start having an effect on the economy.
<h4 class="wp-block-heading">Europe</h4>
European stocks are seeing buying after Trump saying he is initiating talks with Russia's Putin to end the Ukraine war.
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Alphabet Inc Class C (GOOG), NVIDIA Corp (NVDA), and Tesla Inc (TSLA).
In the early trade, money flows are neutral in Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Microsoft Corp (MSFT), and Meta Platforms Inc (META).
In the early trade, money flows are positive in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Market Summary

Hotter PPI Follows Hotter CPI, But Momo Crowd Ignoring Inflation On Trump Hopium

WIIM

COIN

Coinbase shares are trading higher ahead of the company's earnings report. Additionally, Robinhood reported strong crypto trading volumes for Q4 which could be lifting sentiment.

US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading lower on Thursday.</a>
The company reported fourth-quarter adjusted earnings per share of 84 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43688282/us-foods-reports-fourth-quarter-and-fiscal-year-2024-earnings" rel="noreferrer noopener">beating the street view of 80 cents</a>. Quarterly sales of $9.49 billion (up 6.2% year over year) came in line with the analyst consensus estimate.
The company&#8217;s total case volume increased 3.5%, with independent restaurant case volume up 3.2% year over year.
Adjusted gross profit was $1.7 billion, an increase of 7.2% from the prior year. Adjusted gross profit as a percentage of net sales was 17.5%.
&#8220;We delivered another strong quarter which resulted in Adjusted EBITDA growth of 11.7% to a record $1.74 billion for 2024, capping off the final year of our long-range plan,&#8221; said Dave Flitman, CEO.&nbsp;
In the fourth quarter, adjusted EBITDA margin was 4.6%, an increase of 30 basis points compared to the prior year.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/02/43697803/robinhoods-crypto-bet-pays-off-bernstein-predicts-massive-growth-105-price-target" rel="noreferrer noopener">Robinhood&#8217;s Crypto Bet Pays Off: Bernstein Predicts Massive Growth, $105 Price Target</a>
The company exited the quarter with cash and equivalents worth $59 million, compared with $269 million in the year-ago period. Long-term debt at the end of the quarter expanded to $4.819 billion from $4.564 billion prior year.
Outlook: US Foods projects FY25 net sales growth of 4% &#8211; 6%, with adjusted EPS growth between 17% and 23%. The company sees Adjusted<a href="https://www.benzinga.com/calendars/guidance"> EBITDA growth of 8% to 12%.</a>
&#8220;Our future is promising, with a long runway of profitable growth in front of us, giving us confidence in achieving a 5% sales CAGR, a 10% Adjusted EBITDA CAGR and a 20% Adjusted Diluted EPS CAGR through 2027,&#8221; the CEO added.
Price Action: USFD shares are trading lower by 4.5% to $66.77&nbsp;at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43690757/are-ethereum-staking-etfs-on-the-way" target="_blank" rel="noreferrer noopener">Are Ethereum Staking ETFs On The Way?</a></li>
</ul>

Earnings

Guidance

Movers

General

USFD

US Foods Reports Q4 Beat, Eyes Big Growth Through 2027

Oppenheimer analyst Jason Helfstein maintains IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) with a Outperform and lowers the price target from $72 to $70.

Oppenheimer Maintains Outperform on IAC, Lowers Price Target to $70

RBC Capital analyst Rishi Jaluria maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Outperform and raises the price target from $825 to $950.

HUBS

RBC Capital Maintains Outperform on HubSpot, Raises Price Target to $950

RBC Capital analyst Rishi Jaluria maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Sector Perform and lowers the price target from $10 to $8.

FSLY

RBC Capital Maintains Sector Perform on Fastly, Lowers Price Target to $8

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: FedEx (FDX) reported lower-than-expect...

FedEx to separate Freight unit, Nike reports Q2 beat: Morning Buzz

In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Humacyte (HUMA – Research Report), with a price target of $10.00...

TD Cowen Keeps Their Buy Rating on Humacyte (HUMA)

Humacyte ( ($HUMA) ) has issued an update. Humacyte announced that the FDA has granted full approval for SYMVESS, an acellular tissue-engineered ve...

Humacyte Receives FDA Approval for SYMVESS Launch

Benchmark analyst Bruce Jackson raised the firm's price target on Humacyte (HUMA) to $17 from $15 and keeps a Buy rating on the shares. Humacyte an...

Humacyte price target raised to $17 from $15 at Benchmark

Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)

Bullish option flow detected in Hertz Global Holdings with 5,594 calls trading, 1.3x expected, and implied vol increasing almost 4 points to 133.50...

Hertz Global Holdings call volume above normal and directionally bullish

Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning

A&nbsp;class action&nbsp;lawsuit was filed against Humacyte, Inc. ($HUMA) by Levi & Korsinsky on November 18, 2024. The plaintiffs (shareholders) a...

HUMA Lawsuit Alert! Class Action Against Humacyte, Inc.

Humacyte: Upside Potential, But I Will Wait For Revenue Trends

Humacyte (HUMA) and Pluristyx announced an expanded partnership. Pluristyx makes and sells PluriBank iPSC lines as part of their tools, technologie...

Humacyte, Pluristyx announce expanded partnership

AFRM

ENGN

ENVX

EOSE

FREY

HUMA

HUMAW

LUMN

NVDA

RDDT

RZLV

SBUX

SCHL

Press Releases

Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA

Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMA

Legal

Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Penny Stocks

Small Cap

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Health Care

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Humacyte

Intérêt court

Humacyte (NASDAQ:HUMA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL